Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma

Oncology Reports

Volumn 21, Issue 6, 2009, Pages 1585-1592

  Bachleitner Hofmann, Thomas ^a   Friedl, Josef ^a   Hassler, Michaela ^a   Hayden, Hubert ^a   Dubsky, Peter ^a   Sachet, Monika ^a   Rieder, Erwin ^a   Pfragner, Roswitha ^b   Brostjan, Christine ^a   Riss, Stefan ^a   Niederle, Bruno ^a   Gnant, Michael ^a   Stift, Anton ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Allogeneic tumor cell lysate; Dendritic cells; Immunotherapy; Medullary thyroid carcinoma

Indexed keywords

CALCITONIN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; TUMOR CELL VACCINE; TUMOR MARKER; CANCER VACCINE;

ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL LYSATE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HLA TYPING; HUMAN; HUMAN CELL; IMMUNOLOGICAL MONITORING; INGUINAL LYMPH NODE; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; UNSPECIFIED SIDE EFFECT; ADOPTIVE IMMUNOTHERAPY; AUTOTRANSPLANTATION; BLOOD; DENDRITIC CELL; DISEASE COURSE; IMMUNOLOGY; MEDULLARY CARCINOMA; METABOLISM; MIDDLE AGED; PILOT STUDY; THYROID TUMOR; TIME; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; CALCITONIN; CANCER VACCINES; CARCINOMA, MEDULLARY; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MALE; MIDDLE AGED; PILOT PROJECTS; T-LYMPHOCYTES, CYTOTOXIC; THYROID NEOPLASMS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 67649910150     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000391     Document Type: Article

References (26)

1. Giuffrida D and Gharib H: Current diagnosis and management of medullary thyroid carcinoma. Ann Oncol 9: 695-701, 1998.
2. Marsh DJ, Learoyd DL and Robinson BG: Medullary thyroid carcinoma: recent advances and management update. Thyroid 5: 407-424, 1995.
3. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P and Lupoli G: Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 91: 1797-1808, 2001.
4. Bachleitner-Hofmann T, Stift A, Friedl J, Pfragner R, Radelbauer K, Dubsky P, Schuller G, Benko T, Niederle B, Brostjan C, Jakesz R and Gnant M: Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells. J Clin Endocrinol Metab 87: 1098-1104, 2002.
5. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A and Schuler G: Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223: 1-15, 1999.
6. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998.
7. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271-296, 1991.
8. Banchereau J and Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5: 296-306, 2005.
9. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
10. Schott M, Scherbaum WA and Seissler J: Dendritic cell-based immunotherapy in thyroid malignancies. Curr Drug Targets Immune Endocr Metabol Disord 4: 245-251, 2004.
11. Schott M and Seissler J: Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies. Trends Endocrinol Metab 14: 156-162, 2003.
12. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R and Gnant M: Dendritic cell-based vaccination in solid cancer. J Clin Oncol 21: 135-142, 2003.
13. Stift A, Sachet M, Yaghubian R, Bittermann C, Dubsky P, Brostjan C, Pfragner R, Niederle B, Jakesz R, Gnant M and Friedl J: Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res 10: 2944-2953, 2004.
14. Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum WA and Feldkamp J: Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 86: 4965-4969, 2001.
15. Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, Rimoldi D, Cerottini JC, Banchereau J and Palucka AK: Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 192: 1535-1544, 2000.
16. Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C and Dalgleish AG: Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate- pulsed cells: a phase I/II study. BJU Int 94: 412-418, 2004.
17. + T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Res 8: R65, 2006.
18. Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, Vernel-Pauillac F, Boyer A, Baron-Bodo V, Mallard E, Bartholeyns J, Goxe B, Latour N, Leroy S, Prigent D, Martiat P, Sales F, Laporte M, Bruyns C, Romet-Lemonne JL, Abastado JP, Lehmann F and Velu T: Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 55: 819-829, 2006.
19. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C, Jakesz R and Gnant M: In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells. Int J Oncol 22: 651-656, 2003.
20. Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J and Banchereau J: Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 29: 545-557, 2006.
21. Pfragner R, Hofler H, Behmel A, Ingolic E and Walser V: Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma. Cancer Res 50: 4160-4166, 1990.
22. Pfragner R, Skofitsch G, Hoger H, Jech M, Rinner B, Siegl V, Niederle B, Gnant M, Friedl J and Stift A: Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination. Anticancer Res 25: 4225-4230, 2005.
23. Pfragner R, Wirnsberger G, Behmel A, Niederle B, Langle F, Roka R, Mandl A, Purstner P, Auner J and Tatzber F: Biologic and cytogenetic characterization of three human medullary thyroid carcinomas in culture. Henry Ford Hosp Med J 40: 299-302, 1992.
24. Pfragner R, Wirnsberger GH, Ingolic E and Niederle B: Medullary thyroid carcinomas in cell culture-models for future therapies. Wien Klin Wochenschr 114: 279-283, 2002.
25. Bachleitner-Hofmann T, Strohschneider M, Krieger P, Sachet M, Dubsky P, Hayden H, Schoppmann SF, Pfragner R, Gnant M, Friedl J and Stift A: Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma. J Clin Endocrinol Metab 91: 4571-4577, 2006.
26. Dubsky P, Hayden H, Sachet M, Bachleitner-Hofmann T, Hassler M, Pfragner R, Gnant M, Stift A and Friedl J: Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture. Cancer Immunol Immunother 57: 859-870, 2007.